Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05034484 | A Study of ALPN-303 in Adult Healthy Volunteers | PHASE1 | COMPLETED | 72 | — | — | Nov 15, 2021 | Feb 27, 2023 | May 9, 2023 | 2 | Australia |
Type, incidence, and severity of TEAE as assessed by CTCAE
| Arm | Type | Description |
|---|---|---|
| ALPN-303 Regimen A | EXPERIMENTAL | - |
| Placebo Regimen A | PLACEBO_COMPARATOR | - |
| ALPN-303 Regimen B | EXPERIMENTAL | - |
| Placebo Regimen B | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| ALPN-303 | DRUG | Multiple dose levels will be evaluated. |
| Placebo | DRUG | Placebo will be administered |
Summary of Inclusion Criteria: * Able and willing to provide written informed consent * Body mass index 18 to 32 kg/m2 * Agree to avoid strenuous physical activity for 2 days prior to each study visit * Agree to use highly effective contraception during the study (all participants) and for 90 days ...